Figure 4.

ACT001 inhibits LPS-induced NF-κB activation. (A) HEK Blue TLR4 293 cells, which over-express human CD14, TLR4, and MD2, were stimulated with 20 ng/mL LPS and indicated concentrations of ACT001. The NF-κB activity was determined by SEAP assay and cellular viability was measured by CCK-8 Kit. (B) BV-2 NF-κB luciferase reporter cells were treated with 200 ng/mL LPS and the indicated concentrations of ACT001. After 24 h of incubation, the NF-κB activity was determined by the Dual-Glo luciferase assay and cellular viability was measured by crystal violet staining. All experiments were performed 3 times independently and data were given as the mean ± SEM.